Get the Stockscreener App
0.7184
1.52%
-0.0111
Skye Bioscience Inc stock is traded at $0.7184, with a volume of 207.59K.
It is down -1.52% in the last 24 hours and down -11.70% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$0.7295
Open:
$0.695
24h Volume:
207.59K
Relative Volume:
0.99
Market Cap:
$25.25M
Revenue:
-
Net Income/Loss:
$-57.33M
P/E Ratio:
-0.4971
EPS:
-1.4452
Net Cash Flow:
$-42.44M
1W Performance:
-4.33%
1M Performance:
-11.70%
6M Performance:
-39.63%
1Y Performance:
-66.11%
1-Day Range:
$0.695
$0.7497
1-Week Range:
$0.695
$0.85
52-Week Range:
$0.5655
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-06-25 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-15-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛
SKYE News | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) Surges 5% as Key Support Holds, Resistance in FocusPut Wall - newsline.com
SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline, Stock RisesEBITDA Margin Trends - newsline.com
SKYE Stock Chart | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) Holds Near Support Amid Modest GainsDividend ETF - newsline.com
Skye Bioscience, Inc. Amends Articles of Incorporation to Increase Authorized Shares – SEC 8-K Filing May 2026 - Minichart
Skye Bioscience Expands Authorized Shares After Shareholder Approval - TipRanks
Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase - Stock Titan
Skye Bioscience (SKYE) Tumbles 8.8% as Selling Pressure Intensifies, Support in SightFactor Rotation - The Legal Advocate
SKYE Stock Quote Price and Forecast - CNN
SKYE Q1 2026 Earnings: EPS Miss Masks Steady Pipeline ProgressEarnings Manipulation Risk - newsline.com
Skye Bioscience (SKYE) Edges Higher, Testing Resistance Near Key LevelsUpthrust Pattern - The Legal Advocate
Skye Bioscience (SKYE) Edges Higher Amid Renewed Buyer InterestNarrow Range Breakout - The Legal Advocate
Skye Bioscience (SKYE) Holds Above Support After Modest GainTrading Ideas - newsline.com
SKYE Q1 2026 Earnings: EPS Misses Estimates Amid No Revenue, Shares Edge HigherReturn On Assets - The Legal Advocate
Skye Bioscience (SKYE) Edges Higher as Support Holds, Testing Key Resistance at $0.88Volume Oscillator - The Legal Advocate
SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues DevelopmentEarnings Analysis - newsline.com
SKYE: All proposals passed, directors elected, and no stakeholder questions were raised - TradingView
SKYE Q1 2026 Earnings: EPS Slightly Below Estimates, Stock Surges 16% on Strategic ProgressMargin Guidance - The Legal Advocate
Skye Bioscience Rallies; Holiday Week Puts Focus on Tuesday - Bez Kabli
Skye Bioscience Surges 7.7%: Biotech Stock Tests Resistance at $0.81IV Percentile - newsline.com
Skye Bioscience gets approval to open second cohort in study By Investing.com - Investing.com Australia
Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1 - marketscreener.com
Skye Bioscience gets approval to open second cohort in study - Investing.com
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 - The Manila Times
Skye Announces Cohort Review Committee Approved Opening of - GlobeNewswire
Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87 - MSN
Skye Bioscience Faces Nasdaq Compliance Risk Over Equity - The Globe and Mail
[8-K] Skye Bioscience, Inc. Reports Material Event - Stock Titan
Nimacimab obesity trial progresses as Skye Bioscience initiates CBeyond study Part C - Traders Union
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - Moomoo
Skye Bioscience 4Q Loss/Shr 36c >SKYE - Moomoo
UPDATESkye Bioscience Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
Skye Bioscience2026 Funding Rounds & List of Investors - Tracxn
Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026 - Quiver Quantitative
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - GlobeNewswire
Press Release: UPDATE -- Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - Moomoo
Skye Bioscience stock price target cut to $6 by Piper Sandler on cash runway - Investing.com
SKYE Advances CBeyond Program toward Phase 2b Trials - GuruFocus
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
SKYE: Promising Phase 2a combo results, but Q1 net loss and funding risks threaten future operations - TradingView
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Skye Bioscience, Inc. Quarterly Earnings Report - Stock Titan
Number of shareholders of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Skye weight-loss trial combo hits 22% mean loss at 52 weeks - Stock Titan
Biotech Overhyping Obesity Drug Hurt Investors, Suit Says - Law360
Skye Bioscience Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
SKYE Technical Analysis | Trend, Signals & Chart Patterns | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) CFO John P. Sharp files initial Form 3 - Stock Titan
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):